So Lithium or Depakote for Bipolar I?

Ok, so our institution rams down our throats that Lithium>>>>> Depakote. But as I talk to other attendings, they tell me that their residency says Depakote>>>> Lithium. So I setup a poll and want to know, 1) Your preferred mood stabilizer for acute mania? 2) Your preferred mood stabilizer for maintenance bipolar therapy? Any good papers/studies to read on Lithium vs. Depakote?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Source Type: forums

Related Links:

This report describes an urgently established but viable system in one prefecture of Japan for treating COVID-19-infected patients with severe psychiatric symptoms during the COVID-19 pandemic.PMID:34560568 | PMC:PMC8450142 | DOI:10.1016/j.ajp.2021.102859
Source: Asian Journal of Psychiatry - Category: Psychiatry Authors: Source Type: research
CONCLUSION: Incidence risks of medical illnesses are increased in the first year after bipolar disorder diagnosis. Clinicians must carefully evaluate medical illnesses during this period because the mortality rates from medical illnesses are particularly high in people with bipolar disorder.PMID:34558298 | DOI:10.1177/00048674211046891
Source: The Australian and New Zealand Journal of Psychiatry - Category: Psychiatry Authors: Source Type: research
This study explored use of the Internet and digital devices during the pandemic restrictions and its association with physical and mental health changes.Methods: Three hundred sixty seven adults with an SMI diagnosis completed a survey (online or offline) and provided information on access to Internet connexion and devices, internet knowledge, online activities, and barriers to using the Internet. They also self-reported changes in mental and physical health since the beginning of the pandemic restrictions.Results: During the pandemic restrictions 61.6% were limited or non-users of the Internet. The majority had access to ...
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
Curr Med Chem. 2021 Sep 22. doi: 10.2174/0929867328666210922160116. Online ahead of print.ABSTRACTMajor depressive disorder (MDD) and bipolar disorders (BDs), the most severe types of mood disorders (MDs), are considered as among the most disabling illnesses worldwide. Several studies suggested that inflammatory neuroinflammation might be involved in the pathophysiology of MDs, while reporting increasing data on the relationships between these processes and classical neurotransmitters, hypothalamus-pituitary-adrenal axis (HPA), and neurotrophic factors. The assessment of neutrophil/lymphocyte ratio (NLR), platelet/lymphocy...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Source Type: research
CONCLUSIONS: Lumateperone at 42 mg/day significantly improved depression symptoms and was generally well tolerated in patients with major depressive episodes associated with both bipolar I and bipolar II disorders.PMID:34551584 | DOI:10.1176/appi.ajp.2021.20091339
Source: The American Journal of Psychiatry - Category: Psychiatry Authors: Source Type: research
Chemistry. 2021 Sep 23. doi: 10.1002/chem.202103012. Online ahead of print.ABSTRACTAcquiring desirable device performance with deep-blue color purity that fulfills practical application requirements is still a challenge. Bipolar fluorescent emitters with HLCT state may serve to address this issue. Herein, by inserting anthracene core in the deep-blue building blocks, we successfully developed two highly twisted D-π-A fluorescent emitters, ICz-An-PPI and IP-An-PPI , featuring different acceptor groups. Both exhibited superb thermal stabilities, high PLQYs and excellent bipolar transport capabilities. The non-doped OLEDs ...
Source: Chemistry - Category: Chemistry Authors: Source Type: research
CONCLUSIONS: Lumateperone at 42 mg/day significantly improved depression symptoms and was generally well tolerated in patients with major depressive episodes associated with both bipolar I and bipolar II disorders.PMID:34551584 | DOI:10.1176/appi.ajp.2021.20091339
Source: The American Journal of Psychiatry - Category: Psychiatry Authors: Source Type: research
Carbamazepine is extensively used worldwide to treat a wide range of disorders such as epilepsy, peripheral neuralgia and bipolar disorder. Thrombocytopenia and hemorrhage have been identified in multiple carbamazepine-treated patients. However, the underlying mechanism remains poorly understood. Here, we show that platelets undergo apoptosis after carbamazepine treatment. The apoptotic platelets induced by carbamazepine are rapidly removed in vivo, which accounts for thrombocytopenia. We found that carbamazepine treatment attenuates the phosphorylation level of bcl-xl/bcl-2-associated death promoter (BAD), vasodilator-ass...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
tta Crisafulli Suicide in Bipolar Disorder (BD) is a relevant clinical concern. Genetics may shape the individual risk for suicide behavior in BD, together with known clinical factors. The lack of consistent replication in BD may be associated with its multigenetic component. In the present contribution we analyzed a sample of BD individuals (from STEP-BD database) to identify the genetic variants potentially associated with three different suicide-related phenotypes: 1) a feeling that the life was not worth living; 2) fantasies about committing a violent suicide; 3) previous attempted suicide. The sample under analysi...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
American Journal of Psychiatry, Ahead of Print.
Source: American Journal of Psychiatry - Category: Psychiatry Authors: Source Type: research
More News: Bipolar | Divalproex Sodium | Lithium | Mania | Residencies | Students | Study | Universities & Medical Training